Sino Biopharm Buys siRNA Specialist Hygieia in RMB1.2 Billion Chronic Disease Push

Sino Biopharmaceutical ( (HK:1177) ) has issued an update.

Sino Biopharmaceutical has agreed to acquire 100% of pioneering siRNA drug developer Hygieia for up to RMB1.2 billion, to be paid in a mix of cash and new shares, turning Hygieia into an indirect wholly owned subsidiary. The deal, classified as a share transaction under Hong Kong listing rules, is intended to deepen Sino Biopharm’s presence in next-generation therapies by integrating Hygieia’s end-to-end siRNA platform and delivery technologies, which target multiple tissues and address key unmet needs in chronic conditions such as weight management and metabolic disorders, cardiovascular and cerebrovascular diseases, and neurological disorders; management positions the move as a strategic step to build a cardiovascular innovation pipeline and tap the rapidly expanding, trillion‑dollar global chronic disease management market.

The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.

More about Sino Biopharmaceutical

Sino Biopharmaceutical is a Hong Kong-listed pharmaceutical group engaged in the research, development, manufacturing and sale of innovative medicines, with a growing focus on advanced biopharmaceutical technologies. The company targets major therapeutic areas including chronic diseases, where it is seeking to build differentiated pipelines and strengthen its competitive position in large, long-term treatment markets.

Average Trading Volume: 75,132,543

Technical Sentiment Signal: Buy

Current Market Cap: HK$122.2B

See more data about 1177 stock on TipRanks’ Stock Analysis page.